Bayer: launches phase III study in prostate cancer
(CercleFinance.com) - Bayer has announced the further expansion of its global clinical development program for darolutamide against prostate cancer.
A new Phase III clinical trial will investigate the efficacy of darolutamide, in combination with androgen deprivation therapy (ADT), versus ADT alone, in hormone-sensitive prostate cancer in selected patients at high risk of biochemical relapse (BCR).
Darolutamide is already approved under the brand name Nubeqa for the treatment of patients with metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well as metastatic hormone-sensitive prostate cancer (mHSPC).
Bayer estimates that Nubeqa's potential peak sales could exceed E3bn.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
A new Phase III clinical trial will investigate the efficacy of darolutamide, in combination with androgen deprivation therapy (ADT), versus ADT alone, in hormone-sensitive prostate cancer in selected patients at high risk of biochemical relapse (BCR).
Darolutamide is already approved under the brand name Nubeqa for the treatment of patients with metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well as metastatic hormone-sensitive prostate cancer (mHSPC).
Bayer estimates that Nubeqa's potential peak sales could exceed E3bn.
Copyright (c) 2023 CercleFinance.com. All rights reserved.